id stringlengths 36 36 | title stringlengths 0 391 | funder stringclasses 125 values | beneficiary stringlengths 3 1.44k | source_id stringlengths 0 41 | abstract stringlengths 6 4.76k | funding_scheme stringclasses 411 values | label class label 8 classes |
|---|---|---|---|---|---|---|---|
gen_ff8c9190fa6b3386939a878f7039ac1b | Towards a two-terminal nano-electronics via one-dimensional nanowires. | Irish Research Council | Trinity College Dublin | Not available | Early Career / Enterprise Partnership Scheme (Postdoctoral) | 1fellowships_scholarships | |
gen_aef10332666f4ace8ba2398ce471fbf9 | Novel Antimicrobials and their Role in Disease Prevention | Irish Research Council | Athlone Institute of Technology | Not available | Early Career / EMBARK | 1fellowships_scholarships | |
gen_e04b295658e1fffea18513d92a5a2763 | Reformulating Mental Health Law and Policy in Ireland in Light of the UN Convention on the Rights of Persons with Disabilities | Irish Research Council | University of Galway | Not available | Early Career / Employment-Based Programme | 1fellowships_scholarships | |
gen_582cb8376da12a80c8bd1229a8f0aca4 | Gaia bright stars data processing and analysis | Irish Research Council | University College Dublin | Not available | Early Career / European Space Agency Traineeship Scheme | 1fellowships_scholarships | |
gen_f32eae0bce53a30b364b27b8cdf224a9 | Using Big Data sources for the consistent estimation of next-generation route choice models | Independent Research Fund Denmark | Danmarks Tekniske Universitet | 6111-00493A | Trafikmodeller benyttes til vurdering af potentielle infrastrukturprojekter. Idet sådanne projekter er meget dyre og påvirker mange rejsende, er det essentielt at beslutningsgrundlaget er så godt som muligt. Modellerne skal derfor formå at repræsentere det virkelige transportsystem nøjagtigt. Dette er imidlertid ikke en triviel opgave, idet systemet består af rejsende som foretager rationelle eller irrationelle valg i et komplekst vejnet under konstant forandring. Rutevalget udgør en stor og vigtig komponent af enhver trafikmodel, men mange af nutidens rutevalgsmodeller er teoretisk inkonsistente. Desuden er de ofte kalibreret manuelt, baseret på data genereret af spørgeskemaundersøgelser med urealistiske hypotetiske valgsituationer. Der er for nylig blevet udviklet en teoretisk konsistent rutevalgsmodel, men der foreligger endnu ikke metoder til estimation af denne. Projektets formål er at udvikle metoder til konsistent estimation af den nye rutevalgsmodel, der udnytter nye Big Data kilder (f.eks. GPS data). Sådanne datakilder er attaktive, idet de indeholder information om faktisk foretagede valg fremfor valg i hypotetiske situationer. Desuden indeholder de ofte mange observationer. Projektet vil implementere metoden i software, og anvende denne i kombination med GPS data til at estimere Landstrafikmodellen. Dette vil sikre et bedre beslutningsgrundlag for fremtidige infrastrukturprojekter. Landstrafikmodellen anvendes bl.a. af Transportministeriet til projektvurdering. | Postdoc / DFF-Individuel Postdoc / fellowship | 1fellowships_scholarships |
gen_86085572246e142bb839b5831dcfae75 | Deusto International Research School | European Commission | Lund University | CORDIS-665959 | With a proven track in PhD training (more than 1000 PhD in 50 years, 58 in 2013) the Deusto International Research School (DIRS) aims at attracting qualified international Early Stage Researchers for high quality PhD training that enhance research, complementary and transferable skills. DIRS aims are grounded in a solid structure generated around a robust and dynamic ecosystem that encourages and enables cooperation, co-creation and collegiality among 7 doctoral programmes and 24 research groups around four research foci centred on challenges identified in the EU and the Basque Smart Specialisation Strategies: i) Health and Wellbeing, ii) Human Rights, Peace and Conflict Resolution, iii) Sustainable Development and Innovation and iv) Lifelong Learning. UDEUSTO has actively and creatively procured conditions conducive to frequent dialogues between economic, cultural and social actors whose cooperation and exchanges help realise DIRS aims. These dialogues will ensure international and intersectoral mobility, including placements/internships to broaden ESR career employability tracks; cross-fertilisation of ideas and ideation of solutions to societal challenges fuelled by shared concerns and funding. 40 partners formally back DIRS project. 16 MSC PhD candidates will be selected via an open, transparent, merit-based, impartial, equitable and internationally advertised process that will take special care to avoid any form of discrimination. Upon acceptance, PhD candidates will sign an employment contract and will be hosted in an attractive environment to benefit from a shared supervision and mentoring process formally inscribed in the Doctoral Agreement and the individualized research/training development plan (Personal Career Development Plan). Full internationalisation is an essential aspect of DIRS. The COFUND scheme will strengthen the European and International dimensions of the project by consolidating the current rate of ESR (31,25% of PhD students in 2013/2014) | H2020-EU.1.3. / 1.3 Marie Skłodowska-Curie Actions (MSCA) | 1fellowships_scholarships |
gen_f7276dc9fd2cf9e4f66f785415ce63f7 | Investigating Immunosuppression in Beta-catenin-mutated Hepatocellular Carcinoma for Improved Precision Medicine Therapeutics | NIH | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | 1F30CA284540-01 | PROJECT SUMMARY/ABSTRACT Hepatocellular carcinoma (HCC) is the 6th leading cause of cancer-associated mortality in the United States, and is rising due to chronic liver disease and its associated sequalae. Currently, the response rates to current therapeutic paradigms consisting of immune checkpoint inhibitors (ICIs) remain low, and there exist an urgent need for novel combinatorial therapies to improve patient mortality. Lack of response to current ICIs is mainly due to a poor understanding of the tumor immune microenvironment (TIME) and how various HCC driver mutations lead to specific immune phenotypes. Additionally, there currently exist no biomarker-driven therapeutics for patient treatment stratification. ꞵ-catenin-active (encoded by mutated CTNNB1 oncogene) HCCs represent approximately 26-35% of HCCs and respond poorly to ICIs due to ꞵ-catenin driving an immunosuppressive TIME and limiting the effector function of lymphocytes important for anti-tumor immunity. We have developed novel ꞵ-catenin-mutated HCC mouse models where mutant CTNNB1 is co-expressed with either the proto-oncogene MET (ꞵ-catenin/hMet) or nuclear factor erythroid 2–related factor 2 (Nrf2) (ꞵ- catenin/Nrf2). These models represent 11% and 10% of all clinical HCC cases, respectively. Our preliminary studies demonstrate that ꞵ-catenin potentiates tumorigenesis in ꞵ-catenin-mutated HCC, and that directly targeting ꞵ-catenin promotes an inflammatory response driving anti-tumor immunity. Based on these observations, our overarching hypothesis is that ꞵ-catenin actively suppresses the adaptive immune response in the TIME and targeting ꞵ-catenin or its downstream immunomodulatory factors may improve susceptibility to ICIs. To investigate, I propose the following specific aims, which will uncover novel mechanisms of ꞵ-catenin signaling in the HCC TIME, aimed at developing precision medicine therapeutics. Specific Aim 1: We will determine the immune cells activated following ꞵ-catenin inhibition, and investigate whether there is in vivo synergy combining ꞵ-catenin inhibition and ICIs through single-cell RNA-sequencing (scRNA-seq) and multiplex immunohistochemistry. Thus, we will identify mechanisms of immunosuppression caused by ꞵ-catenin activation in ꞵ-catenin-mutated HCC. Specific Aim 2: Based on our preliminary data showing interferon regulatory factor- 2 (IRF2) repression in ꞵ-catenin-mutated HCC, we hypothesize that ꞵ-catenin-mutated HCCs may be sensitized to ICIs, or even show spontaneous tumor regression, upon re-expression of IRF2 as a result of enhanced immune response. We will use synthetic biology approaches to selectively induce IRF2 expression at various timepoints in tumorigenesis and monitor tumor burden. We will then use scRNA-seq on the lymphoid population to identify cell types and states regulated by IRF2, and test combination of IFNg (which induces IRF2) + ICI as a therapeutic modality. Contribution to Training: This proposal combines rigorous research training in liver cancer biology, immuno-oncology, and advanced bioinformatic analyses with an excellent clinical education, to aid my development as a future academic physician-scientist at the forefront of immune dysfunction in cancer. PROJECT NARRATIVE Hepatocellular carcinoma (HCC) is increasing in incidence due to the sequalae of chronic liver disease, with no significant recent improvement in patient survival due to a lack of biomarker-driven therapeutics. ꞵ-catenin- activation (mutated CTNNB1 oncogene) represents a molecular subset of HCC cases which are resistant to current immunotherapies. This proposal will investigate mechanisms of ꞵ-catenin activation driving immunosuppression in the tumor immune microenvironment, with our results paving the way for precision medicine therapeutics for ꞵ-catenin-mutated HCC. | Training, Individual | 1fellowships_scholarships |
gen_326e53e533739f06ddc08fbacb22f50b | Elucidating the distinct roles of T cell-polarized microglia in glioblastoma suppression and progression | NIH | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 1F31CA284773-01 | Project Summary/Abstract Glioblastoma is a grade IV diffuse astrocytoma, the deadliest and most common form of adult brain cancer. Standard of care extends survival by approximately 1-18 months, with the poorest benefits being seen by elderly patients (>70yrs). New forms of immune-based therapies, including immune checkpoint inhibitors (ICI), may turn the corner in treatments for primary and recurrent glioblastoma. Unfortunately, no clinical trial so far has shown major benefits in either survival or immune engagement for these patients. Recent findings suggest that gliomas harbor multiple and intertwined cellular sources of immune suppression that dampen ICI-initiated responses. Thus, one solution may be to not only enhance effector T cells by blocking checkpoints such as CTLA-4 and PD- 1, but to also target the immune suppressive niches in glioblastoma, the largest of which is comprised of glioma- associated microglia and macrophages (GAMs). In fact, GAMs are a highly attractive target and have been depleted in pre-clinical and clinical studies via CSF1R inhibition (PLX3397). This approach, however, yielded mixed responses in models and no response in patients. Another path may be to reprogram GAMs, but we lack insights into the pathways that promote anti-tumor GAMs. Therefore, identifying the cellular and molecular regulators of pro- and anti-tumor GAM states is the next step in unlocking new therapeutic avenues. Recent work by the Kaech lab showed that CTLA-4 blockade in orthotopic mouse models of glioblastoma reduced regulatory T cell (Treg) infiltration, increased ‘helper’ Th1 cell infiltration, and microglia exposed to Th1 cell-derived IFNg were reprogrammed into an antigen presenting (MHCII+), tumor-phagocytosing (AXL+/MER+) state; in concert, these effects significantly increased survival. This proposal will investigate how GAMs, especially the brain resident microglia, acquire and maintain distinct functional states with the hypothesis that Treg-specific signaling sustains tumor-promoting GAMs during glioblastoma progression while Th1 T cells induce tumor-killing GAMs during an effective ICI-initiated response. Two specific aims are proposed to interrogate this hypothesis. The first aim will employ single-cell spatial transcriptomics to address whether Tregs and Th1 cells are extrinsic regulators of GAM states through direct contact and/or secretory signaling, and whether these interaction axes exist in human glioblastoma. The second aim will define the intrinsic AXL/MER and related pathways regulating GAM state ‘switching’. In summary, this work will better inform GAM-targeting interventions by defining how infiltrating T cells and GAM-intrinsic signaling pathways coordinate the dynamic biology underlying pro- and anti-tumor GAM states. This application outlines the applicant’s proposed training plan, which includes diverse and multidisciplinary research mentorship, training in cutting-edge and advanced techniques, and development of broader scientific skills such as collaboration and effective communication. The research and training outlined in this proposal will prepare the applicant to conduct innovative, rigorous, and impactful research. Project Narrative Glioblastoma is the most common adult brain cancer and has remained incurable since it was first identified over two centuries ago. A central reason for this failure in treatment lies in the heterogenous and immunosuppressive nature of these malignancies, and its ability to evade the immune system from destruction. This proposal will identify how microglia and macrophages, the largest non-tumor component of the microenvironment, can adopt opposing “tumor killing/tumor promoting” activation states and how manipulation of these different states may redirect progressing glioblastoma toward regression. | Training, Individual | 1fellowships_scholarships |
gen_db6e347d0d24b9b1e809cda492e9dba8 | Targeting a Novel Pocket on ITGAV | NIH | UNIVERSITY OF CALIFORNIA, SAN DIEGO | 5K00CA274649-04 | Project Summary. Cancer deaths remain at an all-time high in the United States leaving an urgent clinical need to develop novel therapeutic strategies to help patients. The lack of effective treatments is in part due to underlying complexities in cancer that current scientific approaches are just beginning to uncover. Technological advances are rapidly changing the landscape of scientific discovery; for example, the combination of mathematical modeling in tandem with laboratory based validation leading to better combinational therapies to treat cancer. For this reason, I propose training in both with the F99/K00 Predoctoral to Postdoctoral Fellow Transition Award. For the F99 phase, the dissertation research, I will focus on laboratory based research skills to identify and propose a novel therapeutic to treat cancers. In a high level CRISPR screen targeting about 580 genes on the cell surface we found that Integrin Alpha V (ITGAV) is essential for the survival of solid tumors (colon, pancreatic, and breast cancer). To validate ITGAV as the most essential integrin we designed a second layer screen targeting all 26 integrins and found that ITGAV and Integrin Beta 5 (ITGB5) are the only essential integrins in solid tumors. Interestingly, integrins must for an obligate heterodimer between an alpha and a beta subunit of which ITGAV and ITGB5 are one of the known 24. As the more essential pair, ITGAV was probed with a high-density CRISPR tiling scan and we found a small pocket to be essential for ITGAV function and it was amendable to small molecule binding. A structure based analysis found a loop structure of the beta pair of ITGAV interacts with the discovered pocket, leading to our hypothesis that the pocket is essential for the heterodimer stability between ITGAV and its beta pair. Indeed, from a high-throughput screen of 500 small molecules we found one compound that appears to bind in our pocket and disrupt the heterodimer between ITGAV and ITGB5. Further validation of this potential will be the remaining work to be done for the dissertation research and upon completion, will fill an unmet clinical need since no there no FDA approved drugs targeting integrins approved for cancer indications. To further advance the potential to treat cancer I plan to use mathematical modeling approaches to identify novel therapeutic strategies by understanding the complexities of cancer signaling during the K00 phase, the proposed postdoctoral work. To study complex cancer signaling, in collaboration with Dr. Pirrotte, we generated kinase activity scores in cells where ITGAV was knocked out. With this data we can model the effects of signaling as it relates to measurable changes in the cancer cells. Specifically, we will study cell cycle control, which is inhibited with ITGAV loss. Additionally, we can model known inhibitors to common signaling cascades as novel combinational therapeutic strategies. To confirm our model, I will use laboratory based skill developed during the F99 phase. Overall with the training with the F99/K00 award I will gain skills to be able to build mathematical models to study cancer and validate those models with laboratory based skills. This will allow me to become and independent research and leading scientist in translational research. Project Narrative The proposed research aims to fill an unmet clinical need in treating aggressive cancers such as colon, pancreatic, and breast. We found that Integrin Alpha V (ITGAV) is necessary for the survival of these cancers and that a novel pocket on its structure can be targeted with a drug. Additionally, we will investigate the complex signaling controlled by ITGAV to propose combinational therapies and create new therapeutic strategies to treat these cancers. | Other Research-Related | 1fellowships_scholarships |
gen_ba76733fcaf394b4ddaad0330ab9e79c | Impact of interferon λ signaling on lung macrophage function and type 17 immunity during bacterial super-infection following influenza | NIH | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | 1F31HL164031-01A1 | Abstract Lung diseases and syndromes caused by respiratory pathogens represent a leading cause of death worldwide. Each year, influenza infections result in a significant number of fatalities, a majority of which are complicated by secondary bacterial super-infection. Primary influenza infection has been shown to increase susceptibility to secondary methicillin-resistant Staphylococcus aureus (MRSA) infection by altering the pulmonary host immune response and damaging the lung epithelial barrier, leading to increased morbidity and mortality. Macrophages, both lung-resident and those recruited to the lung, are important in super-infection resolution as they engulf, degrade, and present bacterial antigen to adaptive immune cells, ultimately leading to activation of type 17 cells, which promote pathogen clearance. While the role of interferon-(IFN)α/β during super-infection has been well characterized, type III IFNs have not been as extensively studied within the context of the lung. Data shows that IFNα/β are involved in type 17 attenuation after primary influenza infection, which may indicate that IFNλ exhibits similar inhibitory functions due to overlapping signaling pathways, although the potential for unique functions on lung cells is unresolved. Our lab has preliminary data suggesting that administration of exogenous IFNλ during super-infection reduces bacterial uptake by neutrophils and monocyte-derived cells, but the specific cell subsets impacted are unknown. I hypothesize that lung-resident macrophages are sensitive to IFNλ and that IFNλ signaling impairs phagocytosis and the type 17 immune response during super-infection. In the proposed studies, I will determine which myeloid subsets express the IFNλ receptor (IFNLR1) and identify how intact or disrupted IFNλ signaling broadly impacts lung injury and resolution after infection. More specifically, these experiments will determine how IFNλ impacts MRSA uptake and the initiation of a type 17 immune response during super- infection. IFNλ administration has been considered for therapeutic potential, and the outcomes of this proposal will shed light on potential caveats to the use of IFNλ as a possible treatment method during super-infection. Further, demonstration of the effects of IFNλ on myeloid cells will potentially be applicable to several other settings where an antiviral interferon response is observed. Project Narrative A severe complication of influenza infection is secondary Staphylococcus aureus, and previous data has shown that type I interferons produced during influenza infection result in a defective bacterial immune response. Type III interferons are a more recently discovered family of interferons that share signaling pathways with type I interferons. This project will determine the role of type III interferons in impairment of the immune response against secondary bacterial infection by decreasing lung macrophage function and subsequent type 17 immune induction. | Training, Individual | 1fellowships_scholarships |
gen_e95833b1c6f1cf20f2c55078aede28f4 | Elucidating the Host Metabolic Response to Consumption of Kombucha-associated Microorganisms | NIH | UNIV OF NORTH CAROLINA CHAPEL HILL | 1F31AT012138-01A1 | PROJECT SUMMARY Kombucha is a popular fermented tea that contains probiotics. This beverage has seen a surge in popularity in the United States since the turn of the century and is purported to have many health benefits. Some of these health claims have been cursorily examined, however, none have been rigorously tested and the mechanistic interactions between the microbial components of Kombucha and the host remains unexplored. I will elucidate the host metabolic response to consumption of Kombucha-associated microbes (K. microbes), thereby informing its use in complementary health approaches. The impact of individual probiotic microbes on human health is difficult to deconvolute as humans consume a complex diet, have trillions of gut microbes (including many unidentified species), and measuring host-microbe interactions is not feasible in human subjects. Therefore, animal model systems are essential to investigate the effects of consuming probiotics, including those in Kombucha, on host physiological processes. Caenorhabditis elegans is an excellent model system to explore how K. microbes modulate the host pathways that govern lipid homeostasis, because their microbiomes are easily manipulated through the food source provided and they are a well-established system to study metabolism and the aging process in vivo. I have established a standardized method to maintain C. elegans on a diet exclusively consisting of K. microbes that is consistent with the community found in the fermenting culture (confirmed through 16S rRNA sequencing). In preliminary investigations, I observed that populations of C. elegans exclusively consuming K. microbes, as compared to a control diet (E. coli, the standard laboratory food source), have altered expression of core lipid metabolism genes (e.g., beta-oxidation, fatty acid desaturation), decreased fat levels, and an increased median lifespan. Critically, the molecular mechanisms by which K. microbes alter host physiology is completely unknown. Therefore, I plan to use molecular and genetic approaches in C. elegans to systematically identify the molecular mechanisms that govern the host response to K. microbe consumption and elucidate the components of Kombucha that are necessary and sufficient to confer the observed metabolic and lifespan phenotypes. The proposed experiments will provide unprecedented insight into the mechanism by which K. microbe consumption reconfigures host metabolism. PROJECT NARRATIVE Kombucha, a fermented tea that contains probiotic microbes, has seen a surge in popularity in the United States since the turn of the century. Kombucha is purported to have many health benefits, however, none have been rigorously tested and the molecular relationship between the microbial components of Kombucha and the consumer remains unexplored. The impact of individual probiotic microbes on human health is difficult to deconvolute, therefore, I will use C. elegans as a model to elucidate the molecular mechanisms by which Kombucha-associated microbes may promote health and longevity. | Training, Individual | 1fellowships_scholarships |
gen_5649e81278b9a9a3f17a7cfbb845e30f | Prognostic modeling of pediatric tracheostomy-associated respiratory tract infections | NIH | JOHNS HOPKINS UNIVERSITY | 1K23HL163331-01A1 | PROJECT SUMMARY: Each year over 4,000 children undergo tracheotomy and account for more than 20,000 hospitalizations annually most commonly due to acute tracheostomy-associated respiratory infections (TARI). These hospitalizations are most often due to Pseudomonas aeruginosa infection. Efforts to improve the care of children with tracheostomy are challenged by the limited body of evidence on how patient factors, features of P. aeruginosa itself, and the child's immune response impact the risk of recurrent infection. This proposal will address this critical knowledge gap by identifying and characterizing prognostic factors for frequent rehospitalization in children hospitalized for TARI. In this K23 Mentored Career Development Award, Dr. John Morrison will: 1) leverage existing data from a six-center prospective cohort study of children hospitalized for TARI to identify clinical factors associated with recurrent TARI hospitalization; 2) prospectively determine the association of pathogen-specific factors and features of the host immune response with frequency of recurrent TARI hospitalization, and 3) derive a novel prognostic model incorporating clinical and molecular factors to identify patients at increased risk for recurrent TARI hospitalization. Achieving these aims will facilitate Dr. Morrison's long-term goal of leading prognostically-stratified interventional studies aimed at improving outcomes for children with tracheostomy and others affected by frequent respiratory infections. The applicant has dedicated his career to improving the care for children with chronic respiratory failure and other medical complexity as a physician-scientist. He is an Assistant Professor of Pediatrics with the Johns Hopkins University (JHU) School of Medicine at Johns Hopkins All Children's Hospital (JHACH) who seeks a mentored career development award during which he will develop the advanced training, education, and experience to become an independently funded investigator in biomarker-informed prognostic models and risk- stratified clinical trials in children with tracheostomy. This proposal will provide Dr. Morrison with the support needed to advance his career by 1) acquiring knowledge on the development and application of prognostic modeling, 2) developing expertise in conducting biospecimen-based translational research, 3) preparing to conduct a prospective, multicenter study validating a prognostic model and examining therapeutic strategies, and 4) expanding his practical understanding of individual- and system-level factors contributing to recurrent admissions among children with tracheostomy. Dr. Morrison will be supported by the extensive resources of the Institutes for Clinical and Translational Research at JHACH and JHU and has assembled a strong team of mentors with expertise in biomarker discovery, biomarker-informed prognostic modeling, and risk-stratified clinical trials. He will also pursue coursework through the JHU Bloomberg School of Public Health in biostatistics, molecular epidemiology, and clinical trial conduct to complement his experience in the basic and clinical sciences and acquire the skills necessary to transition to independence. PROJECT NARRATIVE: Little is known regarding why children with tracheostomy experience recurrent respiratory infections despite receiving clinically appropriate antibiotic therapy. This proposal seeks to derive a novel prognostic model that incorporates clinical factors and mechanistically-based laboratory measures of pathogen antibiotic resistance and host immune response to identify children at greatest risk for recurrent tracheostomy-associated respiratory infections (TARIs). The findings of this work under a career development award will provide the basis for future risk-stratified interventional trials employing targeted therapies to reduce the frequency of TARI hospitalization among children with tracheostomy. | Other Research-Related | 1fellowships_scholarships |
gen_dc5c55153ecc276aadf90021a7654e47 | Cambridge Conservation Initiative: executive director's post | Arcadia Fundation | University of Cambridge | 360G-ArcadiaFund-2751 | To develop and consolidate the initiative. | Leadership / Strategic | 2institutional_funding |
gen_0e34c70918811ea2799fcd1e1515840d | Cambridge Conservation Initiative: Endowment of Directorship | Arcadia Fundation | University of Cambridge | 360G-ArcadiaFund-3874 | To establish an endowment fund for the Cambridge Conservation Intiative Directorship | Leadership / Strategic | 2institutional_funding |
gen_bff8d9705e6861bcc4dcbe6e4d3502a7 | LSH&TM - MRC/UVRI Uganda Research Unit on AIDSUVRI Uganda (at LSH&TM) - DTA 2019-2029 | Medical Research Council | MRC/UVRI and LSHTM Research Unit Uganda | HRCS22_01023 | No abstract available for this analysis | HRCS Research Uncodeable / Studentship | 2institutional_funding |
gen_e52b4b32e7dfd0a623e23c4c6a1cdc3e | Research on Research Institute Extension - CTWS-Leiden | Wellcome Trust | Leiden University | HRCS22_13616 | No abstract available for this analysis. | No Research Activity assigned | 2institutional_funding |
gen_f462b3222300687a05103720cf36dea8 | LMICSS - Wellcome Centre for Infectious Diseases Research in Africa | Wellcome Trust | University of Cape Town | HRCS22_13694 | Total number of current applications in progress for LMICSSs by Administering Organisation (for all Programmes they administer): 1Total number of current applications in progress for LMICSSs to be held at the AAP/Centre to which the application relates: 1 | No Research Activity assigned | 2institutional_funding |
gen_40d549a089ccdd006d633c804b14339e | Cardiff University - Integrative Neuroscience | Wellcome Trust | Cardiff University | HRCS22_20655 | No abstract available for this analysis. | Missing/Incomplete | 2institutional_funding |
gen_c3f20d179d55d62a749deed96b02bf6e | Gates Foundatoin | Association of Public and Land-Grant Universities | INV-030353 | to provide general operating support | Postsecondary Education / U.S. Program | 2institutional_funding | |
gen_7fded4bcd4de0ad6117a93b376fe9f60 | Gates Foundatoin | BARR Center | INV-032176 | to provide general operating support | Discovery and Translational Sciences / U.S. Program | 2institutional_funding | |
gen_e16549ef0249cd0fbe5f1163919f4a31 | Structural Grant for the University of Copenhagen reNEW Node | Novo Nordisk Foundation | University of Copenhagen | NNF21SA0073732 | Not available | Research Projects (Between 10 MDKK and 50 MDKK) / Centres / Award | 2institutional_funding |
gen_4e85fd68731fb886063aad52c9403cbc | Vermont Center on Behavior and Health | NIH | UNIVERSITY OF VERMONT & ST AGRIC COLLEGE | 5P30GM149331-02 | PROJECT SUMMARY Overall Plan The overarching goal of this application for a Phase 3 Center of Biomedical Research Excellence (COBRE) award is to firmly establish the Vermont Center on Behavior and Health (VCBH) at the University of Vermont (UVM) as a sustainable center of research excellence. This multidisciplinary center investigates relationships between personal behavior (lifestyle) and risk for chronic disease and premature death. VCBH made considerable progress during Phases 1 and 2 towards becoming a vibrant and sustainable center. VCBH established a strong record of external grant support and peer-reviewed publications with $165.1 million in total cumulative funding, including $18.3 million from awards to COBRE Project Leaders (PLs), and 917 articles in peer-reviewed journals, including 515 listing PLs as 1st or co-authors. PLs succeeded in obtaining NIH, foundation, and industry awards as PIs, Project PIs, and Co-Is. Other Phase 1 and 2 notable accomplishments included establishing an NIH-supported UVM Tobacco Center of Regulatory Science with an initial P50 award that was renewed as a U54, twice renewing an NIH T32 training award in clinical addictions research now in years 31-36, and establishing the new HRSA-supported UVM Center on Rural Addiction and a new NIH T32 training award in neurobiological addiction research. VCBH cores continue to support a vibrant monthly lecture series, annual national conferences, and guest editorship of an annual special issue of the peer-reviewed journal Preventive Medicine based on the conferences. VCBH collaborations with other COBREs continue to grow, with VCBH PI Dr. Higgins chairing two COBRE External Advisory Committees and serving as a member of a third. In Phase 3, we propose to sustain VCBH competitiveness in obtaining external grant support and fostering new research and dissemination initiatives. We will continue mentoring early career investigators, leveraging our three cores that have strong institutional support and broad reach, and coalescing VCBH collaborations around five areas of scientific strength, each with its own working group. An innovative Pilot Project Program will be leveraged to support early-career investigators and generate preliminary data for grant applications in current areas of strength and to foster new research directions. We are confident that with Phase 3 support, VCBH is well positioned to succeed as a sustainable, impactful, multidisciplinary center of research excellence. NARRATIVE Many individuals persist in personal behaviors or lifestyle (substance abuse, physical inactivity/obesity) that significantly increase risk for chronic disease and premature death. This relationship between personal behavior and disease risk is firmly established, but much remains to be learned about why certain individuals are more likely to engage in risky behaviors and how to promote behavior change. | Research Centers | 2institutional_funding |
gen_8c99aac3b299c75756e5c9abf800b026 | Administrative Core | NIH | BOISE STATE UNIVERSITY | 5P20GM148321-02 | PROJECT SUMMARY ─ ADMINISTRATIVE CORE Boise State University is an emerging research university with an expanding base of investigators working on solutions to national and global healthcare problems. The objective for the proposed COBRE in Convergent Engineering and Biomolecular Science (CEBS) is to enhance collaborative and convergent research among Boise State University’s growing cohort of engineers and biomolecular scientists pursuing biomedical research in devices, sensors, and systems. The administrative core (AC) will oversee the career development opportunities for research project leaders and CEBS associated investigators. The AC will organize (1) a professional development committee, (2) an internal advisory committee (IAC), and (3) an external advisory committee (EAC). The AC will schedule regular committee meetings, including an annual review with the EAC to review program progress and elicit feedback. The AC will support professional development through conferences, grant writing workshops, convergent Science of Team Science training, seminar series, and travel and networking opportunities. The AC will provide fiscal support through grants accounting, hiring, travel, purchasing, and annual progress reporting. The AC will oversee the creation and management of a consolidated Fabrication, Characterization, and Testing Core from existing engineering service facilities. The AC will implement a Pilot Project grant program for new and established investigators who propose research in the CEBS thematic area. An undergraduate summer internship will also be established and managed by the administrative core. In managing these activities, it is the goal of the Administrative Core to sponsor growth and training for multidisciplinary teams working to contribute solutions to the growing global need for medical devices and sensors to address human healthcare problems. | Research Centers | 2institutional_funding |
gen_609aea2b42819bde0f3309d9d7b9a935 | Finnish centre of excellence in Randomness and STructures (FiRST) | Research Council of Finland (AKA) | Aalto University | Not available | Unknown | 2institutional_funding | |
gen_5f4d509a68a2ae0849aa6a27e8884227 | Centre of Excellence in Music, Mind, Body and Brain | Research Council of Finland (AKA) | University of Helsinki | Not available | Unknown | 2institutional_funding | |
gen_6c23c155ac34db20dcca1e343c5a25fc | Multidisciplinary center of excellence in antimicrobial resistance research | Research Council of Finland (AKA) | University of Turku | Not available | Unknown | 2institutional_funding | |
gen_9aee441a1b2856e1df674df88a83d472 | Finnish Centre of Excellence in Tax Systems Research | Research Council of Finland (AKA) | Tampere University | Not available | Unknown | 2institutional_funding | |
gen_4e664b31aeb6b808b520ab2c12a16415 | Center of Excellence in Complex Disease Genetics | Research Council of Finland (AKA) | University of Helsinki | Not available | Unknown | 2institutional_funding | |
gen_6d825c28b1fcffeed27f9488329eccca | Centre of Excellence of Inverse Modelling and Imaging | Research Council of Finland (AKA) | Lappeenranta-Lahti University of Technology LUT;Finnish Meteorological Institute;Aalto University;University of Eastern Finland;University of Helsinki;Oulu University Hospital;Tampere University;University of Jyväskylä | Not available | Unknown | 2institutional_funding | |
gen_0f5ae82f4208dc976efa70186a6f16da | Centre of Excellence in Research on Ageing and Care / Consortium: CoE AgeCare | Research Council of Finland (AKA) | University of Helsinki | Not available | Unknown | 2institutional_funding | |
gen_5a11b83f9c323612433460e977440519 | Centre of Excellence in Law, Identity and the European Narratives / Consortium: EuroStorie | Research Council of Finland (AKA) | University of Helsinki | Not available | Unknown | 2institutional_funding | |
gen_dcd191220967a9c5acda20544267ee45 | ARC Centre of Excellence for the History of Emotions | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_28289261d3a0e890fd7ef57768ef111d | ARC Centre of Excellence - In Plant Energy Biology (CPEB) | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_c51647f5f8f361b244070119d14aae24 | ARC Centre of Excellence - Innovative science for sustainable management of coral reef biodiversity | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_69fb25414464689f40d5ca6cb0bac4e3 | Centre for Stem Cells and Tissue Repair | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_55d76b30402cf4eb01e697e0eaf8318a | Centre for Quantum Computer Technology | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_5716268df94eb7976ec56995e230b703 | ARC Centres of Excellence - Grant ID: CE200100012 | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_7293a73e6c71e1673ab801e44db64ffa | Centre for Complex Dynamic Systems and Control | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_f678cff76c2dd4d226041930417ea7a1 | ARC Centres of Excellence - Grant ID: CE200100008 | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_7e5884810fe137680a959cc2d2cb71fb | ARC Centres of Excellence - Grant ID: CE230100032 | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_5dcb79808be3b734f02eb580cd01b17c | The Australian Centre for Functional Nanomaterials | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_d2975a8fc54cc584b5f819f49af76acb | Centre for Mathematical and Statistical Modelling of Complex Systems | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_481bef80c87c987d8e9d57312525dddd | ARC Centre of Excellence in Cultural and Media Industries | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_4321a91dee672252555942f5641492db | Australian Centre for Plant Functional Genomics | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_d2a8b6b4c791ed60a22f17efe9a4e324 | ARC Centre of Excellence - Coherent X-ray Science | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_e42833eb7424ec54c71316bba8503cfd | ARC Centres of Excellence - Grant ID: CE170100015 | Australian Research Council (ARC) | Unknown | Not available | Unknown | 2institutional_funding | |
gen_39d2e6b2f4bf209018a580b047495056 | Ministerio de Ciencia, Innovación y Universidades | UNIVERSITAT POMPEU FABRA | CEX2024-001431-M | Not available | Unidades «María de Maeztu» | 2institutional_funding | |
gen_0a5ccf4a91c496e82f21db26fedf9892 | Ministerio de Ciencia, Innovación y Universidades | FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III | CEX2024-001442-S | Not available | Centros de Excelencia «Severo Ochoa» | 2institutional_funding | |
gen_427d4605066693e16ba16ae2ba73a2b8 | Ministerio de Ciencia, Innovación y Universidades | AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) | CEX2024-001445-S | Not available | Centros de Excelencia «Severo Ochoa» | 2institutional_funding | |
gen_fed3bbb92c6efc13269da61278ebeaa8 | Ministerio de Ciencia, Innovación y Universidades | UNIVERSIDAD DE BARCELONA | CEX2024-001451-M | Not available | Unidades «María de Maeztu» | 2institutional_funding | |
gen_78b5af25524281e5c557329f0bb6c83e | Chair for aerodynamics, dedicated to radial turbomachinery | French National Research Agency (ANR) | ISAE-SUPAERO - Département d'Aérodynamique Energétique et Propulsion | Not available | Unknown | 2institutional_funding | |
gen_f7601c0f095aa7fd327b4e4a0804c867 | Establishing a Chair for the Study of Imagination and Society at the Instituto de Ciências Sociais, ULisboa | European Commission (EC) | INSTITUTO DE CIENCIAS SOCIAIS | Not available | Unknown | 2institutional_funding | |
gen_cec12bad66f93a24f1f572efaaf9ca57 | E-SENSE - Sciences de l’Energie pour une société durable | French National Research Agency (ANR) | Université de Picardie Jules Verne | Not available | Excellences sous toutes ces formes / Programme France 2030 | 2institutional_funding | |
gen_2745c48d1a7aa57f4dd90b36a99c1cc6 | Clinical Services Department | Medical Research Council | London School of Hygiene and Tropical Medicine | HRCS22_01349 | The Clinical Services Department exists to support clinical research at the Unit by providing primary health care to staff and their family members, medical care to study participants, primary health care to the population of West Kiang, and access to paediatric and internal medical services to the general public. Both outpatient and inpatient services are offered at the Fajara site. The Department supports research with specific clinical skills, such as ultrasound, GI endoscopy and bronchoscopy. More intensive studies are hosted in the ward. Alongside this, the Department supports local healthcare training institutions by providing clinical attachments to all levels of nursing students, medical students and doctors in training. The department focuses on Quality Improvement in healthcare, with an active programme of projects aimed to improve the care delivered in the department. A suite of guidelines have been developed and are publicly available. We have developed an electronic medical record system, which enables us to record clinical activity for day-to-day operational reasons, but also gives us access to data that can be used to improve quality and to better understand the conditions seen in the Department. The Department hosts small research projects which answer questions that arise during clinical practice. Examples have included studies of the relationship between respiratory illness and air quality, validation of a locally produced buffer for a point of care test and a study of antimicrobial usage. Collaborations are sought with organisations and individuals who can further the objectives of the Department, particularly when they are able to offer skills which are not currently found within the Department. | 8.1 Organisation and delivery of services / Unit | 2institutional_funding |
gen_d9de690a4243d131c848b603896df46c | Research Services Theme | Medical Research Council | London School of Hygiene and Tropical Medicine | HRCS22_01351 | This is part of the Research Services Theme. This project focuses on Research Services and is made up of three elements, namely Research Services - Data Science Research Services - Governance and Research Support Research Services - Laboratories | HRCS Research Uncodeable / Unit | 2institutional_funding |
gen_377b53607bd80292b168fed48891b383 | Vietnam Africa Asia Programme Core Grant Renewal, 2022 to 2029 | Wellcome Trust | University of Oxford | HRCS22_20998 | Our ten-year vision is to have local, regional and global impact on health by leading a locally driven research programme on infectious diseases in Southeast Asia. We will deliver our vision by fulfilling four aims: Aim 1. Reduce the burden of infectious diseases through research Aim 2. Strengthen our research culture Aim 3. Strengthen our networks and partnerships Aim 4. Increase the local, regional, and global impact of our research Our dominant activity will be research (aim 1), with its delivery, relevance, and sustainability supported by aims 2 and 3, and its impact secured by aim 4. We will achieve our aims through a collaborative network of multidisciplinary researchers in Vietnam and Indonesia, capable of responding rapidly to escalating infectious disease threats and implementing science-led change within health systems. Our research priorities are: • New and re-emerging infectious diseases • Drug resistant infections • Climate change impact on infectious disease epidemiology • Development and implementation of new health technologies We will ensure that our research priorities and activities remain locally relevant and sustainable through extensive public and community engagement. We will strengthen our research culture, and nurture the careers of local researchers and operational staff, supporting their development and promoting their leadership. | Infrastructure | 2institutional_funding |
gen_ed0f8d2af33bde721d1c4f4fe34b9c34 | Gates Foundatoin | Columbia University | INV-023818 | to provide for general operating support | Polio / Global Policy and Advocacy | 2institutional_funding | |
gen_de3ad9c302d6e061e66e6760df5f7254 | Training in Pharmacological Sciences | NIH | VANDERBILT UNIVERSITY | 5T32GM149363-02 | Project Summary/Abstract: The long-term goal of this training program is to develop members of a diverse workforce with rigorous training in an area of biomedical science and to foster a deep understanding of the principles of pharmacology to create scientists who will be well positioned to participate in the process of moving basic science discoveries to much needed therapies. This training will be accomplished in an interdisciplinary and inclusive environment that brings together trainees from multiple institutions who represent a broad range of scientific interests and a shared desire to understand the principles that underlie the development of safe and effective therapies. A cohort of 3 trainees will be appointed for the second and third year of their graduate training, a stage in their training where pharmacology-specific training is best delivered and solidified. We aim to train scientists equipped with the principles of the discipline of pharmacology who are uniquely prepared to identify and solve research questions in the biomedical sciences. Mastery of the principles of pharmacology will allow trainees to serve as leaders in transitioning discoveries into therapies. To this end we have developed a predoctoral training program that will: provide each trainee with the foundational tenants of the discipline of pharmacology such as receptor theory, drug metabolism, and pharmacokinetics; develop the professional skills necessary for success; support individual research mentoring that provides directed research in an area of biomedical science of interest to the trainee alongside discipline-specific training; and evaluate the attainment of individual trainee and program goals. Timely and actionable feedback on the progress of trainees is provided by a competency-based assessment plan developed in collaboration with a select group of like-minded predoctoral training programs. All facets of the proposed program are supported by a comprehensive evaluation plan designed to both assure the development of individual trainees and provide feedback to improve the overall training program. These experiences are supplemented to build competence in research ethics, scientific rigor, presentation of scientific data, and assessment of data. We convey to trainees the expectation and the tools to pursue life-long learning as an essential component for success. Professionalism will be intentionally addressed to impart skills in areas such as communication, teamwork, mentoring, and self-assessment in order to aid in the development of resilience, integrity, and leadership. These program aims are supported by longstanding strengths that include the history of collaboration amongst the partner institutions, the past success of trainees, and a dynamic, intellectually diverse research environment that supports pharmacological investigation. Our goal is to produce trainees who will become leaders in careers found in academic and industrial research, government and regulatory affairs, and education. Project Narrative Funds provide for students to receive training in the discipline of Pharmacology. Training includes both coursework and mentored research. Scientists trained in this area perform important jobs in drug development in universities and industries, product safety, and regulatory affairs. | Training, Institutional | 2institutional_funding |
gen_63df496c2ef14d885f9e454285bca639 | Resource Development Core | NIH | UNIVERSITY OF ALABAMA AT BIRMINGHAM | 1U54DK137307-01 | Innovations to mitigate the global burden of acute kidney injury (AKI) require catalyzers that network investigators and provide them with resources that facilitate discovery, translation and implementation science to impact bedside care, improve policy and dismantle health inequalities. The overarching objective of the Resource Development Core is to incubate novel and strategic approaches to continuously support AKI research across a diverse universe of investigators in the O'Brien Kidney Consortium. This Core will provide a dynamic resource and platform to develop, test and refine innovations that could accelerate pre-clinical and clinical research and then can be offered as part of the Biomedical Resource Cores. The initial focus of this Core will be centered in advanced and quantitative AKI biological characterization and big data analyses. In the pre-clinical area, novel analytical approaches in metabolomics and molecular and functional in vivo imaging will be incubated to probe unique biological characteristics of disease development. In the clinical area, tools for multi-institutional Electronic Health Record (EHR) data management and harmonization and a novel federated learning platform to evaluate Artificial Intelligence (AI)-based tools will be developed. These development areas will be frequently evaluated to assure that the selected tools to be refined or developed are relevant to patients and investigators, and use the most advanced technologies to maintain high standards of validation, reproducibility and transferability tailoring the growing investigator's needs with a pathway to be offered in the Biomedical Cores in the future. To continue to drive innovations in AKI research, the following Specific Aims are proposed. In Aim 1, we will develop an incubator for novel technologies to support pre-clinical research in AKI. Specifically, in Aim 1A, we will develop tools for the examination of the disturbed distribution of small molecules and peptides in AKI. We will develop novel microfluidic methods aimed at high resolution molecular cartography in kidney tissue. In Aim 1B, we will develop molecular and functional kidney-specific imaging and image-analysis approaches in pre-clinical animal models of AKI. Probing for longitudinal evaluations of tissue- scale biological changes with translational positron emission tomography (PET) and magnetic resonance imaging (MRI) will elucidate key molecular, functional, and anatomical alterations during AKI development and in response to novel therapeutics. In Aim 2, we will develop an incubator for digital workspace technologies to support EHR data analyses in AKI. This will include enhancements in existing collaborative digital workspaces to support EHR data management and harmonization (Aim 2A) and the development of a novel federated multi- task learning platform to evaluate AI-based tools (Aim 2B). These aims are forward-thinking to enable novel methodologies to better understand the pathobiology and heterogeneity of AKI. Project Narrative As per the RFA, not needed for individual components. | Research Centers | 2institutional_funding |
gen_ffa030e4e4811d90f67565456b661350 | Einstein-Montefiore Clinical and Translational Science Award Hub | NIH | ALBERT EINSTEIN COLLEGE OF MEDICINE | 5UM1TR004400-02 | The Harold and Muriel Block Institute for Clinical and Translational Research (ICTR) at the Albert Einstein College of Medicine and Montefiore Medical Center serves as the home of our CTSA program. The vision of the ICTR is to improve the health of the Bronx, and other communities that disproportionately and unjustly suffer from poor heath and premature death, by accelerating the translation of biomedical discoveries into effective and sustainable disease prevention and treatment strategies. Created in 2007, the ICTR has transformed clinical and translational research (CTR) throughout Einstein and Montefiore by creating a robust research environment; re- engineering CTR processes; integrating research and healthcare; and developing strong community relationships. The ICTR theme of “Building Bridges in the Bronx and Beyond” underscores the importance of bridging gaps between our researchers, health system leaders, clinicians, patients, communities, and CTSA partners to advance translational science and health equity. The specific aims of the ICTR are to: (1) Catalyze innovations that will enhance the efficiency and effectiveness of translational research. We will support and fund studies with high potential to overcome major CTR roadblocks and health inequities; create methodological and informatics translational science innovations; improve CTR operations, and enhance dissemination and implementation strategies. (2) Engage communities, patients, and other partners early and throughout the translational process. Our new Community and Stakeholder Engagement Research module will transform our learning health system into a “learning health research community”; promote active and continuous bidirectional communication with communities, patients and other partners; facilitate research to identify and mitigate social determinants of health, and enhance uptake of evidence-based programs by target populations. (3) Develop and implement state-of-the-art clinical research and informatics resources and services to improve the rigor, safety, efficiency, effectiveness, and generalizability of CTR. (4) Train, develop, and maintain a skilled, multidisciplinary, and diverse translational workforce to support and lead high quality research with new training and pathway programs to ensure members of historically excluded groups engage in CTR and become research leaders. (5) Partner with other CTSA hubs and the CTSA consortium to accelerate CTR and rapidly respond to urgent public health needs. Our aims are aligned with the new CTSA program goals and will enable the ICTR to maximally contribute to the collective efforts of the national collaborative CTSA consortium to deliver more treatments to more patients more quickly in the Bronx and beyond. The Harold and Muriel Block Institute for Clinical and Translational Research (ICTR), a partnership between the Albert Einstein College of Medicine and Montefiore Medical Center, aims to create a robust and collaborative research enterprise that is committed to advancing clinical and translational science and promoting health equity. The ICTR will catalyze innovations to overcome research roadblocks across the translational spectrum, and will create and maintain a skilled and diverse research workforce, to accelerate the process of turning discoveries in the laboratory, clinic, and community, into health benefits for all. | Non-SBIR/STTR | 2institutional_funding |
gen_6997f73ac37711314e7b42add54a9794 | FEDER - ULHN - FONDEOL | Kohesio | UNIVERSITE LE HAVRE NORMANDIE | https://linkedopendata.eu/entity/Q3681638 | Faced with future climatic and demographic challenges, the development of renewable energies is essential to face environmental challenges. The Public Works (TP) profession is involved in innovation in the construction of production works (power plants, wind farms) and transport (technical galleries, underground and overhead networks), in conjunction with laboratories and universities. This project focuses on the behavior of wind turbine foundations in the Land Sea Continuum zone and associated pathologies. This project constitutes a springboard towards the emergence of a Norman research center in civil engineering applied to renewable energies, and bringing together the University of Le Havre Normandy / INSA Rouen Normandie / ESITC Caen, associated with the CEREMA Normandie Center, which constitutes on a national and territorial level, a center of technical and scientific resources and expertise. International collaboration with the INCT-Infra laboratory; from the Universidade Federal do Ceará (UFC), Brazil, which is carrying out research on a wind farm in the province of Ceará, will make it possible to benefit from feedback from wind farms in coastal areas where the subsoil, subject to water level fluctuations, is the origin of certain pathologies. This research center will work in close collaboration with industrialists in the wind power sector such as Énergie TEAM, (or even Quadrant Energy depending on the characteristics of the soil on the sites) with the provision of a wind farm site for instrumentation and in situ experimentation, particularly in Normandy. This project therefore constitutes a springboard towards the emergence of a Norman research center with a view to responding to European and international calls for projects and will promote international collaboration while allowing strong socio-economic development. | Smarter Europe / Research and innovation / Research and innovation activities in public research centres and centres of competence including networking | 3networking_collaborative |
gen_8212a95ed7d5db862a5eedfb9ba633d6 | Japan and Europe Network for Neutrino and Intensity Frontier Experimental Research 2 | European Commission | THE HENRYK NIEWODNICZANSKI INSTITUTE OF NUCLEAR PHYSICS, POLISH ACADEMY OF SCIENCES | CORDIS-822070 | JENNIFER2 is the evolution and development of the research and communication activities currently being carried on by the JENNIFER MSCA-RISE project, which will be concluded at the end of march 2019. The new challenges of fundamental physics require to use different complementary approaches and to design experiments able to test different “messengers” of the new physics world. The JENNIFER2 project is actually implementing this requirement, putting together research programs at experimental facilities located in Japan including accelerator produced neutrinos (T2K and HyperK collaborations), cosmic neutrinos detection (HyperK collaboration) and a high luminosity electron-positron collider (Belle II experiment at SUPERKEKB) where very rare processes can be observed. The collaboration of European scientists with the Japanese research community is fostered in all experimental issues, while specific knowledge sharing among different experiments is planned in the field of photon detection, computing, real time and remote controls, data analysis algorithms and theory calculations, aiming to build up real synergies on key technologies and research methodologies, as well as on dissemination and outreach. Such cross-fertilization between different experimental approaches is the crucial step towards an effective multi-messenger approach. | H2020-EU.1.3. / 1.3 Marie Skłodowska-Curie Actions (MSCA) | 3networking_collaborative |
gen_31709d50e71442b1ada0918f4a6a57c5 | NBS ACADEMY - A European Academy for integrating Nature-based Solutions (NBS) in teacher education | European Commission (EC) | NATSIONALEN TSENTAR ZA POVISHAVANE KVALIFIKATSIYATA NA PEDAGOGICHESKITE SPETSIALISTI;University of Giessen;University of Gothenburg;EKOSISTEM YURAP;STIMMULI FOR SOCIAL CHANGE;University of Innsbruck;University Of Thessaly;EDEX - EDUCATIONAL EXCELLENCE CORPORATION LIMITED;EUN PARTNERSHIP AISBL | Not available | Unknown | 3networking_collaborative | |
gen_80b4a6fb903239629ac4b8c8d0320099 | CATALYST - European VET Excellence Centre for Leading Sustainable Systems and Business Transformation | European Commission (EC) | ΟΠΑ - ΕΛΚΕ;GRADEZEN INSTITUT MAKEDONIJA AD SKOPJE;FH JOANNEUM GESELLSCHAFT M.B.H.;Iscte - Instituto Universitário de Lisboa;Athens University of Economics and Business;BNW BUNDESVERBAND NACHHALTIGE WIRTSCHAFT EV;BOWEN RHONDA;STOPANSKA KOMORA NA MAL BIZNIS NA REPUBLIKA MAKEDONIJA SKOPJE;ICAA - ASSOCIACAO PARA A ACREDITACAO DA GESTAO DO CAPITAL INTELECTUAL;BEST INSTITUT FUR BERUFSBEZOGENE WEITERBILDUNG UND PERSONALTRAINING GMBH;DIMIOURGIKI SKEPSI ANAPTYXIS;SDSN ASSOCIATION PARIS;Centimfe;APFLBUTZN FAIRES GWAND OG;Collaborating Centre on Sustainable Consumption and Production;SPOROS CIRCULAR SOLUTIONS PRIVATE COMPANY SPOROS KYKLIKES LYSEIS IKE;PRIVATE SCIENTIFIC INSTITUTION, INSTITUTE FOR RESEARCH IN ENVIRONMENT, CIVIL ENGINEERING AND ENERGY, SKOPJE | Not available | Unknown | 3networking_collaborative | |
gen_4073199a02b72f557dd9fc27a6793415 | Strategic partnership to develop open educational resources for teaching digital citizenship | European Commission (EC) | Arbeitskreis Ostviertel e.V.;Athens Lifelong Learning Institute - Civil Non Profit Organisation;S.E.A.L CYPRUS (CYPRUS ORGANIZATION FOR SUSTAINABLE EDUCATION AND ACTIVE LEARNING);ASOCIATIA TEAM 4 EXCELLENCE | Not available | Unknown | 3networking_collaborative | |
gen_3a5465ea5c0847a95b02844dcc743888 | European Joint Programme on Rare Diseases | European Commission | Charles University in Prague; BULGARIAN ASSOCIATION FOR PROMOTION OF EDUCATION AND SCIENCE; AZIENDA OSPEDALIERA UNIVERSITARIA SENESE; UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | CORDIS-825575 | As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profit from coordination on a European and international scale. RD research should be improved to overcome fragmentation, leading to efficacious use of data and resources, faster scientific progress and competitiveness, and most importantly to decrease unnecessary hardship and prolonged suffering of RD patients. In the specific context of the massive generation, need for reuse and efficient interpretation of data, introduction of omics into care practice and the structuration of RD care centers in European Reference Networks, it appears crucial and timely to maximize the potential of already funded tools and programmes by supporting them further, scaling up, linking, and most importantly, adapting them to the needs of end-users through implementation tests in real settings. Such a concerted effort is necessary to develop a sustainable ecosystem allowing a virtuous circle between RD care, research and medical innovation. To achieve this goal, the European Joint Programme on RD (EJP RD) has two major objectives: (i) To improve the integration, the efficacy, the production and the social impact of research on RD through the development, demonstration and promotion of Europe/world-wide sharing of research and clinical data, materials, processes, knowledge and know-how; (ii) To implement and further develop an efficient model of financial support for all types of research on RD (fundamental, clinical, epidemiological, social, economic, health service) coupled with accelerated exploitation of research results for benefit of patients. To this end, the EJP RD actions will be organized within four major Pillars assisted by the central coordination: (P1): Funding of research; (P2): Coordinated access to data and services; (P3) Capacity building; (P4): Accelerated translation of research projects and improvement outcomes of clinical studies. | H2020-EU.3.1. / 3.1 Societal Challenges - Health | 3networking_collaborative |
gen_d73b3baaab3c200069acda287deb8aab | Earth Journalism Network - Biodiversity Media Initiative | Arcadia Fundation | Internews | 360G-ArcadiaFund-4304 | To support the capacity-building of local journalists to investigate and report worldwide on the threats to biodiversity and conservation-based solutions. | Governance / Strategic | 3networking_collaborative |
gen_d2fdfa1dd515278d668fc7f5081acaa0 | Open Book Futures | Arcadia Fundation | Lancaster University | 360G-ArcadiaFund-4882 | To help develop the infrastructures, business models, networks and resources to support open access books publishing by small-to-medium-sized publishers, non-profits and scholarly libraries | Books / Strategic | 3networking_collaborative |
gen_1fc7e20a404d86f1958b795147cf212b | Safeguarding the ocean for future generations: Advancing equity, science and capacity | Arcadia Fundation | Deep Ocean Stewardship Initiative (DOSI) | 360G-ArcadiaFund-4825 | To support the operations of the Deep-Ocean Stewardship Initiative (DOSI), so that it can continue to provide evidence-based advice to inform international policy concerning the management and conservation of the deep ocean. | Governance / Strategic | 3networking_collaborative |
gen_384bae0285b3e133e771aec41a1f845a | Survey of digital resources in African universities | Arcadia Fundation | Association of Commonwealth Universities | 360G-ArcadiaFund-2831 | To assess the need for, and improve engagement with, digital resources in African universities. | Other / Strategic | 3networking_collaborative |
gen_9e50ca04c99fc285f2dd9456f2b05c0b | Earth Journalism Network | Arcadia Fundation | Internews | 360G-ArcadiaFund-3738 | To support capacity building of local journalists to investigate and report worldwide on the threats to biodiversity and conservation-based solutions. | Governance / Strategic | 3networking_collaborative |
gen_94af8265b62cdf536e4b14fc37340765 | Offline Internet Consortium | Arcadia Fundation | Arizona State University Foundation | 360G-ArcadiaFund-4834 | To provide access to offline materials to communities with no internet access. The project will bring together organizations with an interest in providing offline internet to under-served communities. It will support the development of new technology, additional content, and outreach | Other / Strategic | 3networking_collaborative |
gen_7a0e5f435a621a1063e4a1216cf92ba8 | Berkman Center for Internet and Society | Arcadia Fundation | Harvard University | 360G-ArcadiaFund-3160 | To promote open access at Harvard, and other universities and institutions, through consultation and collaboration, exploring cyberspace, sharing in its study & pioneering its development. | Other / Strategic | 3networking_collaborative |
gen_00acfe49348e44ac392a068216181ee1 | Millennium Seed Bank Partnership | Arcadia Fundation | Royal Botanic Gardens Kew | 360G-ArcadiaFund-3454 | To expand the partnership's work in biodiversity rich low- and middle-income countries. | On-site conservation / Strategic | 3networking_collaborative |
gen_9a3611e0058c8431d901802a17aeabf8 | Program on Information Justice and Intellectual Property | Arcadia Fundation | American University Washington College of Law | 360G-ArcadiaFund-4383 | The project will produce high impact research, provide training to a global network of change makers, and connect a global expert network to a global community of researchers, libraries, museums, archives and digital rights activists active in international copyright policy making. | Intellectual property rights / Strategic | 3networking_collaborative |
gen_392ace8434d7971d6a8910e5e0d44b59 | Promoting science for all | Arcadia Fundation | British Science Association | 360G-ArcadiaFund-2737 | To help the association reposition itself as a public body dedicated to promoting science for all. | Discretionary / Discretionary | 3networking_collaborative |
gen_6f64a91544aaf727ae1109457062f385 | Cambridge Conservation Initiative: Collaborative Conservation Research Fund | Arcadia Fundation | University of Cambridge | 360G-ArcadiaFund-3873 | To support collaborative research among the initiative's partners to address high priority biodiversity conservation issues. | Leadership / Strategic | 3networking_collaborative |
gen_6e6a07e3dad08cbcc323fdbc9c9d148b | Millennium Seed Bank Partnership | Arcadia Fundation | Royal Botanic Gardens Kew | 360G-ArcadiaFund-2837 | To expand the partnership's work in biodiversity rich low- and middle-income countries. | On-site conservation / Strategic | 3networking_collaborative |
gen_7ce0f781326a413bf3e672a10718548d | Africa Research Universities Alliance, Centre of Excellence for Non-Communicable Diseases | Economic and Social Research Council | University of Nairobi | HRCS22_11558 | The project seeks to develop a strong collaborative research and training platform, the ARUA Centre of Excellence on Non-Communicable Diseases (ACE-NCD), anchored at five ARUA member universities: Nairobi, Makerere, Ibadan, Ghana and Witwatersrand - working closely with other universities on the continent and UK universities. Specifically, ACE-NCD shall seek to 1. Form a strong network of researchers broadly addressing the problem of NCDs in Africa. Researchers will be drawn from ACE-NCD universities, University of Glasgow and University of Leicester, as well as regional and international universities. Research teams' activities will revolve around six initial thematic areas: Prevention, mechanics of disease, multi-morbidity, bio-banking/biomarkers, models of care, and big data. 2. Bring on board other ARUA and non-ARUA African Universities, especially those that are less-research intensive. Each ACE-NCD spoke university will serve as a regional hub, actively engaging universities within their countries and regions: Ghana and Ibadan targetting West Africa, Nairobi and Makerere focussing on Eastern and Central Africa, and Witwatersrand on Southern Africa. Once on-board, these additional universities will actively collaborate with all members institutions across the continent and indeed the world. This approach will ensure the organic structured growth of the network leading to intra-Africa research capacity-building in NCDs. 3. Provide training and capacity-building in support of NCD research through Masters and PhD programmes (where students will be co-supervised by faculty drawn from the network) and post-doctoral training attached to existing and new research projects. 4. Develop and mount targeted short courses and capacity-building workshops and seminars offered both face-to-face and through e-learning. 5. Develop strong research collaborations with other global networks, initially with the World Universities Network where NCDs is one of its four key pillars and in which Nairobi and Ghana are active members with existing related research projects. 6. Build strong collaborations with African governments, policy-makers, non-university, research institutions, professionals, private sector players, and civil society through the regional hub approach for co-design and co-production to ensure relevance, usefulness, high quality of the research outputs. 7. Develop a vibrant research culture across the network, breaking down traditional silos within and across the member universities to form multi-institutional, multi-disciplinary research teams working to develop fundable high-impact research projects that address the challenges within the identified research themes. These projects will also build upon and strengthen on-going related research activities in member institutions. Supporting activities will include identification, dissemination and exploitation of funding opportunities, training on writing winning grant proposals, support in proposal preparation. | 2.6 Resources and infrastructure (aetiology) / Research Grant | 3networking_collaborative |
gen_bf2fe0f960ab3ef9cf072c371ec0152d | Gordon Research Conference | Ataxia UK | McMaster University | HRCS22_11882 | Sponsorship of CAG Triplet Repeat Disorders Gordon Research Conference and Seminar 2023 | HRCS Research Uncodeable | 3networking_collaborative |
gen_581ce066bd7ee036e9a34e41e3c45b87 | Advancing African Neuroscience Report | Wellcome Trust | University of Cape Town | HRCS22_12201 | The purpose of the Showcasing African Neuroscience meeting was to facilitate a dynamic and interactive stakeholder engagement process that would: highlight the best examples of research in basic and clinical African neuroscience, explore potential for enhancing the interface between them in the African research-context, and provide a platform to highlight the significant potential for new discovery from within the continent. Wellcome Trust supports a wide range of research, looking for potential areas of growth and opportunity, globally. Potential in the African neuroscience research-landscape was identified as one such area. Through conversations, a survey with African neuroscientists, and assistance from other groups already embedded in this landscape, the concept for a strategic meeting was born, with the aim of showcasing exciting neuroscience in African ecosystems, articulating prevailing challenges, and discussing ways to overcome them. The African neuroscience community led the engagement process, with support from Wellcome. A subsequent series of workshops drilled further into issues raised, starting discussions on how best to address them. This report builds on these discussions. In it, we highlight early advances in neuroscience research in Africa, and outline a framework for further development of African neuroscience to explore the unique challenges facing brain health and development. | 2.6 Resources and infrastructure (aetiology) | 3networking_collaborative |
gen_e5cbf809314bead4da65e98371267b99 | Opend Data Commons Spinal Cord Injury | Spinal Research | University of Alberta | HRCS22_12288 | Workshop to provide information and training on Open Data Commons on SCI to all in the filed. | HRCS Research Uncodeable | 3networking_collaborative |
gen_65f565f0cd0cd67973b42941e739ad1e | Depression Update: Dissemination Activiies | Wellcome Trust | Fundmed Pesquisa, Ensino e Inovacao | HRCS22_12423 | A Lancet-World Psychiatric Association Commission on Depression reflecting the work developed over three years by a group of world experts was launched in February 2022. The Commission's state of the art overview of depression provides a timely and unique opportunity for dissemination of knowledge and awareness-raising activities regarding depression. Key goals: 1) Support the organization of a global Commission launch webinar (completed February 16, 2022); 2) Organize and support regional webinars focusing on state of the art knowledge on depression involving policy makers, researchers, individuals with lived experience of depression, and clinicians; 3) Provide materials for dissemination of state of the art knowledge on depression by the World Psychiatric Association and other key partners. | No Research Activity assigned | 3networking_collaborative |
gen_ec33874896cf02db1d51094d23840e04 | Women in Bioinformatics and Data Science Latin America: Conference and Boot Camp | Wellcome Trust | Open Collective Foundation | HRCS22_12441 | No abstract available for this analysis. | 1.4 Methodologies and measurements | 3networking_collaborative |
gen_a27969be2b8166cb3ff41bb9d0b3e737 | Leveraging PHFI’s networks to disseminate recommendations from HCN policy briefs | Wellcome Trust | Public Health Foundation of India (PHFI) | HRCS22_12636 | The proposed work aims to convene stakeholders-health professionals, academia, civil society organisations, think tanks and policy makers to disseminate the recommendations from the policy brief on climate resilient health systems developed by the Health and Climate Network(HCN). The Public Health Foundation of India(PHFI) and its sister organisation- Centre for Chronic Disease Control(CCDC) are strategically poised to deliver the stated objectives given the extensive networks and collaborations already existing as a platform for transformative work with the health systems in India. PHFI's Centre for Environmental Health , recognised as a Centre of Excellence by the Government of India's Ministry of Health and Family Welfare within its National Program for Climate Change and Health, is engaged in providing technical inputs for development of an implementation framework for green and climate resilient health systems which will be customised for use across every state in India. CCDC's Health and Environment Leadership Platform(HELP), established collaboratively with Health Care Without Harm works with private hospitals to commit to decarbonisation as part of the Race to Zero initiative of UNFCCC for COP 26 and beyond. The team will leverage recommendations from the specific brief and related briefs on energy, transport and nutrition to enhance uptake and implementation. | 8.3 Policy, ethics and research governance | 3networking_collaborative |
gen_a3552c65356b76d4f064500a82416327 | INGSA learning & outreach | Wellcome Trust | University of Auckland | HRCS22_12667 | This proposal repurposes funding that Wellcome had intended for use to support LMIC delegate travel to the INGSA biennial conference. It would now enable acceleration of our Online Outreach and Training Strategy. Our current funding envelope pre-dates the pandemic, and did not anticipated the extent of online delivery now required. We have tried hard to transform programming with existing resources, but gaps remain. Will now focus on delivery of accessible, inclusive and interactive capacity-building online. We have content that can be turned into pedagogically-robust modules and made available via a reputable learning platform. Deliverables include: 1. “INGSA Shorts” series of 2-3 minute videos which condense learning/wisdom from the 2021 conference (estimated cost: $12,000 NZD) 2. Minimum three MOOC-style courses, framed around the conference's themes: Science Advice in Crisis (i.e. lessons learned from the pandemic); Science advice for complex/long-term issues (i.e. foresight/resilience; Evidence/democracy. Content drawn from 2021 conference and other Wellcome/IDRC funded programming including past LMIC workshops, the Covid-19 comparisons, Knowledge Associates projects. This approach leverages the full complement of INGSA programming (estimated cost: $28,000 NZD) We will work with new INGSA Board and LMIC partners to co-design, contextualise and field-test material, ensuring that content and format is robust and appropriate to context. | No Research Activity assigned | 3networking_collaborative |
gen_0156c211d89e7df794009e4f72a4c246 | Expanding the Health and Climate Network agenda in Latin America | Wellcome Trust | Brazilian Institute for Consumers Defence | HRCS22_12672 | Considering the current discussions on the urgency for food systems transformation and climate change mitigation, in view of the UN global events Food Systems Summit and COP26 and their outcomes, Idec proposes to articulate partners and deepen discussions at national and regional levels, influencing the political agenda. The proposal's objectives are: 1) To translate and disseminate the four Health and Climate Network (HCN) briefings in order to expand dialogue with strategic partners in Latin America involved in COP26; 2) To promote discussions to deepen connections on current food systems and their outcomes on the people's and planetary health in Brazil and Latin America. Proposed activities are: a) To translate to Portuguese and Spanish and disseminate the four briefings in Idec's own media and explore other media and share them among strategic partners in Latin America; b) To present the HCN Briefing 1 on Food Systems in strategic meetings, to discuss its recommendations in Brazil; c) To fund investigative journalism from a well-recognized journalism agency to further deepen the discussions raised in Briefing 1, producing in-depth materials about food systems and climate agenda; d) To develop podcast episodes on topics related to Briefing 1 targeting key stakeholders on the climate agenda. | No Research Activity assigned | 3networking_collaborative |
gen_94c9f3f1fe55efecd470fc80f847a9f4 | Health - Climate - Transport Nexus: Dissemination of Policy Messages | Wellcome Trust | SLOCAT Partnership on Sustainable, Low Carbon Transport | HRCS22_12676 | Tackling transport emissions has positive impacts. The benefits of transforming mobility paradigms spans across the notion of planetary health that includes human health and the health of our planet. Whether it is curbing emissions, reducing deaths in road crashes, enabling healthy lifestyles, supporting mental health with reclaimed streets or better integrating spatial and transport planning; the transport-air pollution-health-climate nexus is a multiplier. Aim: Strengthening the nexus to advance two complementary objectives by March 2022: • Capitalise on the interdependence between the enablers and disruptors of transport systems transformation and health to influence climate action policy and investment frameworks. • Facilitate medium-, long-term strategic collaborations beyond the transport community. Intended Outcomes • Mutually-reinforcing benefits of transport, health & well-being and climate action better understood. • Economies of scale and costs of inaction soundly established and clearly communicated. • Structured collaboration between a diverse group of experts, thought leaders and policy-makers. • Transport policies and investments defined with an integrated look at health implications and vice-versa. Target Audience • Policy makers, sectors associations, knowledge and academia, governments, multilateral organisations, NGOs, philanthropy and industry • Global, national and local level actors engaged in the international processes on climate change and sustainability (e.g. COP26 and the Second UN Conference on Sustainable Transport). | No Research Activity assigned | 3networking_collaborative |
gen_b97197473c4327059aa487a4a0b6a241 | Metaphoric Stammers and Embodied Speakers: Connecting Clinical, Cultural and Creative Practice in the area of Dysfluent Speech | Wellcome Trust | University College Dublin | HRCS22_12816 | Stammering is a complex, fascinating phenomenon that involves 70 million speakers worldwide, with a ratio of approx. 4 men to 1 woman (Stuttering Foundation). Attended by a history of problematic medical/clinical intervention (Shell 2005; Eagle 2014), it continues to challenge neuroscientists exploring its causes (Per Alm 2006), clinicians developing treatments, and (most of all) the individuals who stammer across the borders of class, culture and ethnicity. Despite the profound significance of cultural responses to the experience of dyslfuency and its expression, the humanities have remained sidelined from mainstream scientific/clinical practice (e.g., Oxford Dysfluency Conference 2017). The present project proposes the first humanities-led network in the area, one in dynamic conversation with clinical/scientific voices around concepts of 'normal' speech and the tenacious alignment of fluency with social 'health' and cultural authority. Building upon presentations/discussions from the recent 'Metaphoric Stammers' conference (2018), three workshops (Clinical, Cultural and Creative) will identify a shared agenda and a series of key objectives, along with the practical structures necessary for delivery. Overall aim: development of a transformative approach to dysfluency with the interdisciplinarity and flexibility necessary to respond to its complex, highly individualised nature, ultimately informing and reshaping public debate/policy around clinical practice and resourcing. | No Research Activity assigned | 3networking_collaborative |
gen_127d4dbf6d07e9a8bf9eb2559f1545a9 | FOSTER (Fight Osteosarcoma Through European Research) consortium - Website Creation and maintenance | Myrovlytis Trust | Institut Gustave Roussy | HRCS22_12888 | The FOSTER consortium (Fight Osteosarcoma Through European Research) proposes to connect multidisciplinary and patient/parent advocate expertise, at a Pan-European level to improve biological, translational and clinical research on osteosarcoma, to ultimately improve survival. With 265 members from across 19 countries, and 8 work packages from biology to late-effects, FOSTER consortium work is overseen by an Executive Committee, with the help of a project manager: to implement a strategic research plan agenda with regular meetings where knowledge sharing can be freely developed; to pursue the aim of gaining a comprehensive overview of current osteosarcoma biology knowledge and trial situation, and thus tackle the current gaps and remaining challenges in osteosarcoma. The FOSTER consortium WEBsite purposes will be improve communication toward professionals from every discipline from biology to clinic, especially young in career investigators, patients and parents whom life have been or are impacted by osteosarcoma and general public. It will communicate on the FOSTER consortium activities, meetings and events, increase visibility of FOSTER consortium, favour multiprofessional European collaborations on osteosarcoma, attract new members to further develop FOSTER consortium activities, seek funding for the operation of the consortium and the studies that will result from its work. | 7.4 Resources and infrastructure (disease management) | 3networking_collaborative |
gen_a677ddbf2e3bbb32da540bce99ada42a | COVID Kurakani (Covid Conversations): understanding stakeholder perceptions of COVID-19 sequencing in Nepal | Wellcome Trust | BNMT Nepal | HRCS22_12925 | The Wellcome Trust funded Epidemic Intelligence project has implemented large scale genome sequencing for SARS CoV-2 at the only functioning sequencing laboratory in country, and stimulated discussion on the future role of pathogen sequencing and approaches to build capacity in Nepal. COVID Kurakani (Covid Conversations) will engage stakeholders to stimulate increased understanding of the role of pathogen sequencing, allow researchers to listen to, be informed by and respond to community perceptions and concerns around sequencing, build trust between participating communities and the researchers and facilitate capacity building for genome sequencing in the country. Our key goals are: 1. Build capacity among the epidemic intelligence team to develop and deliver high quality public engagement activities surrounding pathogen sequencing for epidemic response. 2. Conduct an EDGE analysis of public engagement status at BNMT. 3. Conduct an internal workshop to design the public engagement strategy, including the senior management team. 4. Utilise media expertise among the research team to develop and deliver a series of panel discussion programmes for national broadcast with three participatory target audiences. 5. Understand community and stakeholder perceptions of COVID-19 sequencing. 6. Address knowledge gaps and concerns among stakeholders to build trust and inform the dialogue surrounding pathogen sequencing. | No Research Activity assigned | 3networking_collaborative |
gen_3ae32202ad3b332e0a3cdff1338c0c98 | Human Cell Atlas 2021 Meetings | Wellcome Trust | Human Cell Atlas | HRCS22_13039 | This year’s Human Cell Atlas General Meeting will convene our community virtually to share updates and insights on new HCA research and initiatives, as well as to highlight the work of the HCA Biological Networks and continue to build on progress from the HCA Biological Network Seminar Series. Key outcomes of this meeting will include a shared appreciation for recent advances and future needs that will facilitate the construction of an integrated atlas; progress toward strategic roadmaps for different organs, tissues, and systems; and an enhanced understanding of how the Human Cell Atlas will provide a healthy reference for the understanding of disease. Event Overview Day 1: Plenary talks and networking opportunities.Themes: HCA Overview, Computational Advancements and Cross-Cutting Approaches Day 2: Poster viewings, biological network interactive sessions, and breakout sessions.Theme: HCA Biological Network updates, and plan to organize to build out roadmaps. Day 3: Plenary talks, panel discussions and networking opportunities.Theme: HCA and Disease Impact, and Defining 10-year plan. A portion of the requested funds will also provide partial support for the 2021 HCA Asia General Meeting, to be held in November or December 2021. | No Research Activity assigned | 3networking_collaborative |
gen_aa9fba53fa1552ac043aadb5699d8508 | Environment-Health Nexus in the Asia-Pacific Region | Wellcome Trust | International Institute for Sustainable Development | HRCS22_13073 | The objective of this project is to reverse the current trends towards environmental degradation while reducing the vulnerability of regional populations to environment-related health impacts in the Asia-Pacific region. Towards that objective, this initiative will aim toward increasing political commitment in the Asia-Pacific to strengthen both environmental and health policy via mainstreaming the environment-health nexus, as well as increasing uptake and capacity to operationalize the environment-health nexus in public policy in this region. This work aims to target the barriers to engagement on nexus issues, and support UN Member States in taking an interdisciplinary approach to intergovernmental exchanges on the environment-health nexus. We will collaborate in developing new policy products and knowledge tools on the environment-health nexus shaped to the Asia-Pacific context. In addition, we will partner in, and inform, a high-level regional dialogue on the environment-health nexus in the Asia-Pacific region. Uptake of health issues in non-health ministries through these knowledge and capacity building tools will serve to elevate health and wellbeing in intergovernmental decision-making, particularly to the desks of the negotiators making environmental decisions, at national, regional and global levels. | No Research Activity assigned | 3networking_collaborative |
gen_ae319340aeaa8cc0de8022cec702bf56 | World One Health Congress 2022 | Wellcome Trust | SingHealth | HRCS22_13301 | The World One Health Congress (WOHC) is the world’s premier congress that takes place biennially for the worldwide One Health community. It aims to profile and advance trans-disciplinary efforts that further our collective understanding of animal-human disease transmission alongside their social and environmental determinants. This Congress is hosted by the SingHealth Duke-NUS Global Health Institute (SDGHI) with organisational support from the SingHealth International Collaboration Office (ICO). Other collaborating agencies include the Ministry of Health, Ministry of National Development, National University of Singapore, Nanyang Technological University, Singapore Management University, Saw Swee Hock School of Public Health, Duke-NUS Medical School and more. WOHC 2022 will serve to increase awareness and understanding of the drivers and global risks of a pandemic threat and ensure that these stay high on the agenda of governments and institutions in the region. The Congress will ultimately help countries to decrease risk by fomenting better surveillance and boost pandemic preparedness. The WOHC 2022 anticipates more than 1,500 professionals from international academic institutions, civil societies, national governments and multilateral organisations. At least 750 participants will attend the face-to-face Congress in Singapore, and another 750 will participate virtually. | No Research Activity assigned | 3networking_collaborative |
gen_93df995adac20092f68f9eae4cfa783d | ReAct Africa Annual Conference 2022. Theme: "Africa’s response to Antimicrobial Resistance: Accelerating One Health National Action Plans implementation for the next 5 years." | Wellcome Trust | ReAct Africa | HRCS22_13541 | ReAct Africa and South Centre Annual Conference 2022 Theme: "Africa’s response to Antimicrobial Resistance: Accelerating One Health National Action Plans implementation for the next 5 years." Antimicrobial resistance is a significant global threat to public health, food security, and development today. In Africa, AMR has been documented to be a problem exacerbated by a high burden of infectious diseases and weak healthcare systems. The existential COVID-19 pandemic has further complicated the situation. The conference comes at an opportune time in July 2022. The conference offers an opportunity for retrospection where experts and key multisectoral stakeholders convene to reflect on lessons learned. The setting allows for context-specific discussions on challenges that are relatable across the region. The conference also provides a forum for sharing best practices across sectors with a one-health approach. The conference will be an opportunity to present the GRAM report results. Leveraging on experience, insights, and tools from countries, NGOs, academia, UN agencies, continental and regional agencies, CSOs, and the private sector, the conference will explore what can be done differently in the subsequent years. Presentations will include scientific poster presentations on diverse research and exhibit best practices that contribute to catalytic action for the next five years. | HRCS Research Uncodeable | 3networking_collaborative |
gen_a28a2a61df4ddf5ff668aaa10e4dbf46 | Advancing the global health agenda with the Paris Peace Forum | Wellcome Trust | Paris Peace Forum | HRCS22_13758 | The Paris Peace Forum will host a series of discussions to maintain the partnership developed by ACT-A (Access to COVID-19 Tools Accelerator) and the governance of global health at the top of the political agenda and further deliver concrete solutions while contributing to the construction of an overall governance framework in the sector. The proposal includes hosting discussions taking place in the framework of a pilot, year-long partnership between the Forum and Wellcome Trust. These discussions would mobilize stakeholders of the Forum’s community and beyond. The Forum would naturally seek Wellcome’s guidance and advice on the scope, topics, invitees, and outputs of these discussions. Stakeholders would be invited to participate in each discussion based on their institutional focus and expertise and on the basis of their capacity to contribute to and implement the desired outcomes. With the support provided by the Wellcome Trust, the Forum could convene two roundtables in 2021, to provide for sufficient time for preparation, eventually for follow-up actions in between and potentially to leverage to key moments in the annual Forum cycle: the Spring meetings of the Paris Peace Forum (May 2021) and the fourth edition of the annual event (11-13 November, 2021). | No Research Activity assigned | 3networking_collaborative |
gen_ae2f6e346919a1ebe8bf8a7b8b18f1a9 | Public and Population Health Open Research Ecosystem in Africa (P2HOREA) | Wellcome Trust | University of the Witwatersrand | HRCS22_14017 | This project seeks to address existing data sharing concerns of African public and population health researchers. It also motivates for the implementation of Africa-led initiatives for data sharing. Using acquired knowledge on global best practices and regional concerns, the project will design sustainable mechanisms to incentivise data sharing. This will involve leveraging our strategic partnerships and adopting artificial intelligence (AI) tools to implement solutions to some of the concerns. We will improve data sharing value chain; simplify access and utilization of data; and strengthen capacity and advocacy towards incentivised data sharing. Using AI tools, we will develop a virtual and physical environment for active and passive identification and curation of a list of publicly funded research data in public and population health in Africa; link researchers and research institutions to reusable publicly funded data; increase awareness and address fears and misconceptions about data sharing; and advocate for institutions to provide best practice rewards when data is shared. These activities will result in improved knowledge, attitude, and practices on data sharing by researchers, institutional data custodians and institutional management; increased collaboration and knowledge generation among researchers; and incentivisation of data sharing at institutional level. The project will promote scientific data findability, access, and reusability while simultaneously addressing data governance and trust concerns, fear of data misuse and exploitation, and ensuring compliance with privacy, security, and ethical standards on data sharing. | 8.3 Policy, ethics and research governance | 3networking_collaborative |
gen_02b25c3c8618bbd1d4d9caef16e1fe17 | GHIAA MAPGuide: creation of access resources and guidance for funders | Wellcome Trust | Global Healthcare Innovation Alliance Accelerator | HRCS22_14254 | The GHIAA MAPGuide enables users to explore a range of approaches used to address key issues in global health agreements. As of 1 November 2021, the MAPGuide contained analysis of 387 provisions from 59 agreements, and our team is constantly working to expand on this. An important next step in widening the impact of the MAPGuide is to create educational resources that present key information and best practice recommendations in a format that can be easily understood by all stakeholders. The objective of this application is to develop materials that provide guidance to global health funders, PDPs and government ministries as they work to develop equitable access policies and ensure that they are translated into actionable agreements. The materials will draw on the agreements and provisions in the MAPGuide to examine the key pillars of equitable access and how they can be achieved through meaningful and enforceable contract terms. This information will be presented on the MAPGuide website in an easy to use format using a combination of infographics and a series of ‘plain English’ articles that explore key topics in more detail. | No Research Activity assigned | 3networking_collaborative |
gen_7660412b1b4180e3050e0bcf9461fda7 | The Research Software Alliance (ReSA) | Wellcome Trust | Code for Science & Society | HRCS22_14399 | Research software is a critical component of open research, and an increased focus on research software challenges will further the objectives of Wellcome Trust’s Open Research programme to maximise research impact. The Research Software Alliance (ReSA) advances the vision that software is valued as a fundamental component of research. This proposal will support ReSA to bring research software communities together to collaborate on the advancement of research software, utilising application of the FAIR principles as a catalyst for this global endeavour.This project seeks USD$157,250 to engage the research software community to apply the FAIR principles to research software. to achieve three aims: 1. FAIR4RS WG project direction to develop agreed FAIR for research software principles 2. FAIR4RS Roadmap leadership to map FAIR for research software projects into a longer-term strategic framework 3. People Roadmap to support the development of career paths and reward structures to complement the FAIR4RS Roadmap This proposal will accelerate the development of an open research system that recognises and supports research software. This will provide researchers with the skills and resources to fully utilise research software, in a system where policy makers and funders value research software, and where organisations adequately reward staff with software expertise. | 1.5 Resources and infrastructure (underpinning) | 3networking_collaborative |
gen_5fa220b2ea353cf097dcbea3f7878510 | Developing an Evidence Generation Platform for Therapeutics with a focus on Low and Middle Income Countries (LMICs) | Wellcome Trust | Coalition for Epidemic Preparedness Innovations | HRCS22_15015 | CEPI’s vision is “creating a world in which epidemics and pandemics are no longer a threat to humanity”. We were established with a mission to accelerate the development of vaccines, but we know that vaccines alone are not sufficient to achieve this vision. COVID-19 uncovered major gaps and opportunities in the therapeutics preparedness and response landscape, including: 1. A serious gap in end-to-end coordination 2. Fragility of upstream research efforts, including short-lived industry interest and insufficient access-friendly funding 3. Specific gaps along the value chain in: evidence generation, host-directed therapeutics, manufacturing scale-up, epidemic- and pandemic-ready policy and regulation, and advocacy for epidemic- and pandemic-specific procurement and country-readiness mechanisms We believe the global community would be well served by CEPI expanding into therapeutics. This would maximise the benefit for global health by utilising CEPI’s well-regarded existing infrastructure, governance and processes. We propose a step-wise entry into therapeutics, starting with areas where existing CEPI capabilities can provide significant value for Therapeutics: evidence generation. Building on these entry points, CEPI will develop a longer-term strategy for how CEPI can best advance therapeutics preparedness and response, and, in doing so, help create a world in which epidemics and pandemics are no longer a threat to humanity. | No Research Activity assigned | 3networking_collaborative |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.